RESUMO
Pantoprazole is a new proton pump inhibitor with a potent antisecretory activity, well defined pharmacokinetics and safety profile. The aim of this single blind, randomized clinical trial was to compare the efficacy of pantoprazole (PAN) 40 mg/day and omeprazole (OME) 20 mg/day in patients with grade I and II GERD (Savary-Miller classification). A total of 120 patients were included (PAN = 60 and OME = 60). In the per protocol/analysis, healing rates at 4 weeks were 76.3% PAN and 71.2% OME (ns), and at 8 weeks 94.7% PAN and 92.9% OME (ns). In the intention to treat analysis, healing rates at 4 weeks were 75% PAN and 70% OME (ns), and at 8 weeks 90% PAN and 86.6% OME (ns). Both pantoprazole and omeprazole were well tolerated with no serious drug related adverse events. Pantoprazole 40 mg/day was found to be safe and effective therapy comparable to omeprazole 20 mg/day in the short-term treatment for reflux esophagitis (grade I and II).
Assuntos
Antiulcerosos/uso terapêutico , Benzimidazóis/uso terapêutico , Esofagite Péptica/tratamento farmacológico , Omeprazol/uso terapêutico , Sulfóxidos/uso terapêutico , 2-Piridinilmetilsulfinilbenzimidazóis , Antiulcerosos/efeitos adversos , Benzimidazóis/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Omeprazol/efeitos adversos , Pantoprazol , Método Simples-Cego , Sulfóxidos/efeitos adversosRESUMO
The paper briefly presents the development of maxillary sinus endoscopy since its beginning, to the employment of Hopkins's optics and "cold light". Based on the data from 48 patients who underwent surgery, the tables summarize indications for endoscopic approach to maxillary sinus in smaller centres, which have been rendered even more remote from large clinical centers due to current situation and traffic conditions. The approach through fossa canina is preferred to the endonasal approach.
